Plant-Derived Cannabinoids as Potential Cancer Treatments: Targets and Mechanisms
A comprehensive review mapped how phytocannabinoids interact with the endocannabinoid system to produce antitumor effects, highlighting CB2 receptors and endocannabinoid-degrading enzymes as drug targets that avoid psychoactive side effects.
Quick Facts
What This Study Found
This review examined how plant-derived cannabinoids (phytocannabinoids) from both cannabis and non-cannabis plants interact with the endocannabinoid system to fight cancer.
The review focused on strategies to avoid psychoactive effects: targeting CB2 receptors (found primarily on immune cells rather than in the brain), inhibiting endocannabinoid-degrading enzymes (FAAH and MAGL), and using non-psychoactive cannabinoids. CB2-selective compounds and enzyme inhibitors showed antitumor activity in preclinical models without the cognitive effects of THC.
Phytocannabinoids from non-cannabis plants were also identified as promising candidates, including compounds that bind cannabinoid receptors and modulate endocannabinoid levels.
Key Numbers
Targets reviewed: CB1, CB2 receptors, FAAH enzyme, MAGL enzyme; non-cannabis plant sources of phytocannabinoids identified; preclinical efficacy across multiple cancer types
How They Did This
Comprehensive review of preclinical literature on phytocannabinoids as cancer therapeutics, focusing on mechanism of action through the endocannabinoid system, with emphasis on non-psychoactive strategies.
Why This Research Matters
The main barrier to cannabinoid-based cancer treatment is psychoactive side effects from CB1 activation. This review mapped alternative strategies that could deliver antitumor effects without the high, potentially making cannabinoid cancer treatments clinically viable.
The Bigger Picture
The discovery that non-cannabis plants also produce compounds that interact with cannabinoid receptors expands the drug discovery pipeline beyond Cannabis sativa and may yield novel antitumor agents with better side effect profiles.
What This Study Doesn't Tell Us
All evidence preclinical. Non-cannabis phytocannabinoids are less well-characterized than cannabis-derived compounds. The translation gap between preclinical antitumor effects and clinical cancer treatment remains substantial.
Questions This Raises
- ?Which non-cannabis phytocannabinoids are most promising for cancer treatment?
- ?Can CB2-selective agents produce meaningful antitumor effects in human cancers?
- ?Would FAAH/MAGL inhibitors be safe for chronic use in cancer patients?
Trust & Context
- Key Stat:
- CB2 receptors and FAAH/MAGL enzymes as non-psychoactive drug targets
- Evidence Grade:
- Comprehensive preclinical review identifying drug targets and mechanisms. No human clinical data for antitumor applications.
- Study Age:
- Published in 2015. Drug development targeting the endocannabinoid system in cancer has continued.
- Original Title:
- Phytocannabinoids for Cancer Therapeutics: Recent Updates and Future Prospects.
- Published In:
- Current medicinal chemistry, 22(30), 3472-501 (2015)
- Authors:
- Patil, K R, Goyal, S N, Sharma, C, Patil, C R, Ojha, S
- Database ID:
- RTHC-01035
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can cannabinoids treat cancer without getting you high?
This review identified strategies that could theoretically work: targeting CB2 receptors (immune system, not brain), using FAAH/MAGL enzyme inhibitors, or using non-psychoactive cannabinoids. However, none have been proven effective against cancer in humans.
Do other plants besides cannabis produce cannabinoids?
Yes. This review identified several non-cannabis plants that produce compounds capable of binding to cannabinoid receptors. These phytocannabinoids could serve as starting points for drug development with potentially different properties than cannabis-derived compounds.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01035APA
Patil, K R; Goyal, S N; Sharma, C; Patil, C R; Ojha, S. (2015). Phytocannabinoids for Cancer Therapeutics: Recent Updates and Future Prospects.. Current medicinal chemistry, 22(30), 3472-501.
MLA
Patil, K R, et al. "Phytocannabinoids for Cancer Therapeutics: Recent Updates and Future Prospects.." Current medicinal chemistry, 2015.
RethinkTHC
RethinkTHC Research Database. "Phytocannabinoids for Cancer Therapeutics: Recent Updates an..." RTHC-01035. Retrieved from https://rethinkthc.com/research/patil-2015-phytocannabinoids-for-cancer-therapeutics
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.